Reivindicaciones

1. Compound of formula (I) <img class="EMIRef" id="495200330-ib0049" /> wherein R<1> is - a phenyl ring, or a 6- or 5-membered heterocyclic ring containing one or more heteroatoms selected from O, N and S; wherein the rings are unsubstituted or substituted at one or more available positions with NH<2> , OH, halogen, phenyl, C<1> -C<6> alkyl (preferably methyl), -O-C<1> -C<6> alkyl (preferably OMe), =O, or =NH; - a fused ring group consisting of 2 or 3 rings, wherein each ring is independently a phenyl ring or a 6- or 5-membered heterocyclic ring containing one or more heteroatoms selected from O, N and S; and wherein each ring is independently unsubstituted or substituted at one or more available positions with NH<2> , OH, halogen, phenyl, C<1> -C<6> alkyl (preferably methyl), -O-C<1> -C<6> alkyl (preferably OMe), =O, or =NH; - NHR<4> , wherein R<4> is a phenyl ring, or a 6- or 5-membered heterocyclic ring containing one or more heteroatoms selected from O, N and S; and wherein the rings are unsubstituted or substituted at one or more available positions with NH<2> , OH, halogen, phenyl, C<1> -C<6> alkyl (preferably methyl), -O-C<1> -C<6> alkyl (preferably OMe), =O, or =NH; or - -CH<2> -R<5> , wherein R<5> is -CN, or a phenyl ring, or a 6- or 5-membered heterocyclic ring containing one or more heteroatoms selected from O, N and S; and wherein the rings are unsubstituted or substituted at one or more available positions with NH<2> , OH, halogen, phenyl, C<1> -C<6> alkyl (preferably methyl), -O-C<1> -C<6> alkyl (preferably OMe), =O, or =NH; R<2> is -(CH<2> )<n> -X, wherein n is 0, 1, 2 or 3, and X is - a phenyl ring, or a 6- or 5-membered heteroaromatic ring containing one or more heteroatoms selected from O, N and S; and wherein the rings are unsubstituted or substituted at one or more available positions with NH<2> , OH, halogen, CF<3> , C<1> -C<6> alkyl (preferably methyl), -O-C<1> -C<6> alkyl (preferably OMe), =O, or -NHC(O)Me; or - a fused ring group consisting of 2 rings, wherein each ring is independently a phenyl ring or a 6- or 5-membered heteroaromatic ring containing one or more heteroatoms selected from O, N and S; and wherein each ring is independently unsubstituted or substituted at one or more available positions with NH<2> , OH, halogen, CF<3> , C<1> -C<6> alkyl (preferably methyl), -O-C<1> -C<6> alkyl (preferably OMe), =O, or -NHC(O)Me; R<3> is H or -(CH<2> )<n> -X, wherein X and n are as defined for R<2> ; or R<2> and R<3> , together to the nitrogen atom to which they are bound, form a pyrrolidine or piperidine ring; or a pharmaceutically acceptable salt or solvate thereof; for use as a medicament. 2. Compound, salt or solvate for use according to claim 1, wherein R<1> is - a phenyl ring, or a 6- or 5-membered heteroaromatic ring containing one or two heteroatoms selected from O and N; and wherein the rings are unsubstituted or substituted at one or more available positions with halogen, -O-C<1> -C<6> alkyl (preferably OMe) or C<1> -C<6> alkyl, (preferably Me); or - NHR<4> , wherein R<4> is a phenyl ring, or a 6- or 5-membered heteroaromatic ring containing one or two heteroatoms selected from O and N; and wherein the rings are unsubstituted or substituted at one or more available positions with halogen, -O-C<1> -C<6> alkyl (preferably OMe) or C<1> -C<6> alkyl, (preferably Me). 3. Compound, salt or solvate for use according to any preceding claim, wherein R<1> is a phenyl ring, or a 6-membered heteroaromatic ring containing one or two N heteroatoms; and wherein the rings are unsubstituted or substituted at one or more available positions with halogen. 4. Compound, salt or solvate for use according to any preceding claim, wherein R<1> is a phenyl ring; wherein the ring is unsubstituted or substituted at one or more available positions with halogen. 5. Compound, salt or solvate for use according to claims 1 or 2, wherein R<1> is NHR<4> , wherein R<4> is a phenyl ring, or a 6-membered heteroaromatic ring containing one or two N heteroatoms; and wherein the rings are unsubstituted or substituted at one or more available positions with halogen. 6. Compound, salt or solvate for use according to claims 1-2 or 5, wherein R<1> is NHR<4> , wherein R<4> is a phenyl ring; wherein the ring is unsubstituted or substituted at one or more available positions with halogen. 7. Compound, salt or solvate for use according to any preceding claim, wherein R<2> is a phenyl ring, or a 6- or 5-membered heteroaromatic ring containing one or more N heteroatoms; and wherein the rings are unsubstituted or substituted at one or more available positions with NH<2> , OH, halogen or C<1> -C<6> alkyl. 8. Compound, salt or solvate for use according to any preceding claim wherein R<2> is phenyl or pyridyl; wherein the rings are unsubstituted or substituted at one or more available positions with NH<2> , halogen or C<1> -C<6> alkyl. 9. Compound, salt or solvate for use according to any preceding claim, wherein R<3> is H or a phenyl ring, or a 6- or 5-membered heteroaromatic ring containing one or more N heteroatoms; and wherein the ring is unsubstituted or substituted at one or more available positions with NH<2> , OH, halogen or C<1> -C<6> alkyl. 10. Compound, salt or solvate for use according to any preceding claim, wherein R<3> is H, or phenyl or pyridyl; wherein the rings are unsubstituted or substituted at one or more available positions with NH<2> , halogen or C<1> -C<6> alkyl. 11. Compound for use according to claim 1, wherein the compound is: <img class="EMIRef" id="495200330-ib0050" /> <img class="EMIRef" id="495200330-ib0051" /> <img class="EMIRef" id="495200330-ib0052" /> <img class="EMIRef" id="495200330-ib0053" /> <img class="EMIRef" id="495200330-ib0054" /> <img class="EMIRef" id="495200330-ib0055" /> <img class="EMIRef" id="495200330-ib0056" /> <img class="EMIRef" id="495200330-ib0057" /> <img class="EMIRef" id="495200330-ib0058" /> <img class="EMIRef" id="495200330-ib0059" /> <img class="EMIRef" id="495200330-ib0060" /> or <img class="EMIRef" id="495200330-ib0061" /> or a pharmaceutically acceptable salt or solvate thereof. 12. Compound for use according to claim 1, wherein the compound is: <img class="EMIRef" id="495200330-ib0062" /> <img class="EMIRef" id="495200330-ib0063" /> <img class="EMIRef" id="495200330-ib0064" /> <img class="EMIRef" id="495200330-ib0065" /> or a pharmaceutically acceptable salt or solvate thereof. 13. Compound for use according to claim 1, wherein the compound is: <img class="EMIRef" id="495200330-ib0066" /> or a pharmaceutically acceptable salt or solvate thereof. 14. Compound, salt or solvate for use according to any preceding claim, for use in the treatment of a congenital disorder of glycosylation, preferably PMM2-CDG. 15. Pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as defined in any of claims 1-13, and a pharmaceutically acceptable excipient.